Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies

British Journal of Dermatology

Volumn 162, Issue 5, 2010, Pages 1144-1146

  Santos Juanes, J ^a   Coto Segura, P ^a   Mas Vidal, A ^a   Galache Osuna, C ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Arthritis; Psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PSORIASIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951248812     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09669.x     Document Type: Letter

References (4)

1. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 371 : 1665 1674. (Pubitemid 351671883)
2. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371 : 1675 1684. (Pubitemid 351671884)
3. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 : 633 640. Erratum in: Lancet 2009; 373: 1340.
4. Pink AE, Fonia A, Allen MH et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010 [Epub ahead of print].